Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jul 20;2005(3):CD001717.
doi: 10.1002/14651858.CD001717.pub2.

Depot perphenazine decanoate and enanthate for schizophrenia

A David  1 , S Quraishi, J Rathbone
Affiliations

Depot perphenazine decanoate and enanthate for schizophrenia

A David et al. Cochrane Database Syst Rev. .

Abstract

Background: Antipsychotic drugs are usually given orally but compliance with medication given by this route may be difficult to quantify. The development of depot injections in the 1960s gave rise to extensive use of depots as a means of long-term maintenance treatment. Perphenazine decanoate and enanthate are depot antipsychotics that belong to the phenothiazine family and have a piperazine ethanol side chain.

Objectives: To assess the effects of depot perphenazine decanoate and enanthate versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes.

Search strategy: We updated previous searches of the Cochrane Schizophrenia Group Register (June 1998), Biological Abstracts (1982-1998), the Cochrane Library (Issue 2, 1998), EMBASE (1980-1998), MEDLINE (1966-1998), and PsycLIT (1974-1998) by searching the Cochrane Schizophrenia Group Register (March 2004). References of all identified trials were also inspected for more studies and industry contacted.

Selection criteria: We compared randomised clinical trials focusing on people with schizophrenia where depot perphenazine decanoate and enanthate, oral antipsychotics or other depot preparations.

Data collection and analysis: We reliably selected studies, quality rated them and extracted data. For dichotomous data we estimated the Relative Risk (RR) with the 95% confidence intervals (CI). Where possible, we calculated the number needed to treat statistic (NNT). Analysis was by intention-to-treat.

Main results: Only four studies (Ahlfors 1980, Eufe 1979, Knudsen 1985c, Tegeler 1979), randomising a total 313 people could be included in this review and this combined with an overall lack of usable data limits any interpretation of results. Perphenazine enanthate was not significantly any better or worse than other depot antipsychotics in most of the main outcomes such as global state, relapse or leaving the study early. We found some differences favouring the control groups for adverse effects. One study (Ahlfors 1980) of six months' duration (n=172), compared perphenazine enanthate to clopenthixol decanoate. There were no differences between the two groups for outcomes of global improvement, relapse and leaving the study early. More people in the perphenazine enanthate group, however, required anticholinergic drugs than those allocated to clopenthixol decanoate (RR 1.12 CI 1.0 to 1.2, NNT 10).A single study (n=64, duration six weeks) compared perphenazine enanthate and its longer acting decanoate ester. Data on relapse and leaving the study early failed to show convincing differences. The enanthate group, however, experienced more movement disorders (RR 1.36, CI 1.1 to 1.8 NNT 5) than those allocated the decanoate ester of the same drug and required more anticholinergic drugs (RR 1.47 CI 1.1 to 2.0, NNT 4).

Authors' conclusions: Depot perphenazine is in clinical use in the Nordic countries, Belgium, Portugal and the Netherlands. At a conservative estimate, a quarter of a million people suffer from schizophrenia in those countries and could be treated with depot perphenazine. The total number of participants in the four trials with useful data is 313. None of the studies observed the effects of oral versus depot antipsychotic drugs. Until well conducted and reported randomised trials are undertaken clinicians will be in doubt as to the effects of perphenazine depots and people with schizophrenia should exercise their own judgement or ask to be randomised.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1.1
1.1. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 1 Death (6 months to 1 year).
1.2
1.2. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 2 Global State: 1. No important improvement (CGI, high score=worse, 6 months to 1 year).
1.3
1.3. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 3 Global State: 2. Needing additional antipsychotic treatment (6 months to 1 year).
1.4
1.4. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 4 Global State: 3. Not improved/worse (6 weeks to 5 months).
1.5
1.5. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 5 Global State: 4. Global judgement of tolerability (medium term 6 weeks to 5 months).
1.6
1.6. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 6 Mental state: Relapse.
1.7
1.7. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 7 Leaving the study early.
1.8
1.8. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 8 Adverse effects: 1. Movement disorders (6 months to 1 year).
1.9
1.9. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 9 Adverse effects: 2. Additional use of anticholinergics ‐ reason why unclear (6 months ‐ 1 year).
1.10
1.10. Analysis
Comparison 1 PERPHENAZINE ENANTHATE: 1. VERSUS OTHER DEPOT ANTIPSYCHOTICS, Outcome 10 Adverse effects: 2. Additional use of antiparkinsonian drugs ‐ reason why known (6 weeks to 5 months).
2.1
2.1. Analysis
Comparison 2 PERPHENAZINE ENANTHATE: 2. VERSUS PERPHENAZINE DECANOATE, Outcome 1 Mental state: Relapse (6 weeks to 5 months).
2.2
2.2. Analysis
Comparison 2 PERPHENAZINE ENANTHATE: 2. VERSUS PERPHENAZINE DECANOATE, Outcome 2 Leaving the study early (6 weeks to 5 months).
2.3
2.3. Analysis
Comparison 2 PERPHENAZINE ENANTHATE: 2. VERSUS PERPHENAZINE DECANOATE, Outcome 3 Adverse effects: Movement disorders (6 weeks to 5 months).
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Ahlfors 1980 {published data only}
    1. Ahlfors UG, Dencker SJ, Gravem A, Remvig J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. Acta Psychiatrica Scandinavica 1980;61:77‐91. - PubMed
Eufe 1979 {published data only}
    1. Eufe R, Wegener G. Double blind compartive trial with 2 depot neuroleptics (perphenazine enanthate and fluphenthixol decanoate with chronic schizophrenia [Doppelblind vergleich von 2 depotneuroleptika (Perphenazin‐onanthat und flupentixol‐decaoat bei chronischer schizophrenie)]. Nervenarzt 1979;50:534‐9. - PubMed
Knudsen 1985c {published data only}
    1. Knudsen P, Hansen LB, Auken G, Waehrens J, Hojholdt K, Larsen NE. Perphenazine decanoate vs perphenazine enanthate efficacy and side effects in a 6 week double‐blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatrica Scandinavica 1985;72(supp 322):15‐28. - PubMed
Tegeler 1979 {published data only}
    1. Tegeler J, Floru L. A comparative study of the longacting neuroleptics perphenazin enanthate and fluspirilene [Eine Vergleichende Untersuchung Der Depot‐Neuroleptika Perphenazin Onanthat Und Fluspirilen]. Pharmakopsychiatrie Neuropsychopharmakologie 1979;12(5):357‐65. [EMBASE 1980018158] - PubMed

References to studies excluded from this review

Angst 1975 {published data only}
    1. Angst J, Woggon B. Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, fluspirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate. Arzneimittel Forschung 1975;25(2):267‐70. - PubMed
Bakke 1973 {published data only}
    1. Bakke O. Clinical experience with depot neuroleptics. Acta Psychiatrica Scandinavica 1973;246:32‐46. - PubMed
Dencker 1994 {published data only}
    1. Dencker SJ, Gios I, Martensson E, Norden T, Nyberg G, Persson R, Roman G, Stockman O, Svard KO. A long term cross‐over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanaote in schizophrenic patients. Psychopharmacology 1994;114:24‐30. - PubMed
Giannelli {published data only}
    1. Giannelli A, Rabboni M, Zarattini F. Clinical profiles of action, individual treatment preferences, affects and contraindications of three depot neuroleptics compared in a multicentre trial [Profili clinici di azione, indicazioni preferenziali, effetti terapeutici e controindicazioni di tre neurolettici depot in trial multicentrico di confronto]. Rivista di Psichiatria 1990;25(1):7‐24.
Kistrup 1991 {published data only}
    1. Kistrup K, Gerlacj J, Aaes‐Jorgensen T, Larsen N. Perphenazine decanoate and cis(z)‐flupenthixol decanoate in maintenance treatment of schizophrenic outpatients. Psychopharmacology 1991;105:42‐8. - PubMed
Knudsen 1985a {published data only}
    1. Knudsen P, Hansen LB, Hojholdt K, Larsen NE. Long‐term depot neuroleptic treatment with perphenazine decanoate I. Acta Psychiatrica Scandinavica 1985;76(supp 322):29‐40. - PubMed
    1. Knudsen P, Hansen LB, Hojholdt K, Larsen NE. Long‐term depot neuroleptic treatment with perphenazine decanoate II. Acta Psychiatrica Scandinavica 1985;76(supp 322):40‐50. - PubMed
Kundsen 1985b {published data only}
    1. Knudsen P, Hansen LB, Larsen NE. Perphenazine decanoate in sesame oil vs perphenazine enanthate in sesame oil. Acta Psychiatrica Scandinavica 1985;76(supp 322):11‐14. - PubMed
Lindholm 1978 {published data only}
    1. Lindholm H, Gullberg BO, Ohman A, Sedvall G. Effects of perphenazine enanthate injections on rolactin levels in plasma from schizophrenic women and men. Psychopharmacology 1978;57:1‐4. - PubMed
Rapp 1972 {published data only}
    1. Rapp W. Preliminary study of perphenazine enanthate in the treatment of chronic schizophrenia. Pharmakopsychiatrie Neuro Psychopharmakologie 1972;5:205‐14. [EMBASE 1980018158]
Rapp 1986 {published data only}
    1. Rapp W, Hellbom E, Norrman O, Palm U, Rodhe K, Forsman A, Larsson M. A double blind crossover study comparing haloperidol decanoate and perphanazine enantate. Current Therapeutic Research 1986;39(5):665‐70.
Rysanek 1982 {published data only}
    1. Rysanek R, Svestka J, Nahunek K, Ceskova E. Experience with perphenazine‐enanthate in the maintenance therapy of schizophrenic psychoses. Activas Nervosa Superior (Praha) 1982;24(4):227‐8.

Additional references

Aaes‐Jorgenson 1985
    1. Aaes‐Jorgenson A. Pharmacokinetics of oral and depot neuroleptics‐Clinical relevance. Symposium Espo. 1 Feb 1985.
Alderson 2004
    1. Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. The Cochrane Library 2004, Issue Issue 1. [In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd]
Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [PDE020600] - PMC - PubMed
Barnes 1994
    1. Barnes TRE, Curson DA. Long term depot antipsychotics. A risk benefit assessment. Drug Safety 1994;10(6):464‐79. - PubMed
Bland 1997
    1. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600. - PMC - PubMed
Curson 1995
    1. Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long‐term depot maintenance of chronic schizophrenic out‐patients: the seven‐year follow‐up of the medical research council fluphenazine/ placebo trial. British Journal of Psychiatry 1985;146:464‐80. - PubMed
David 1994
    1. David AS, Cutting JC (eds). The neuropsychology of schizophrenia. Hove, E.Sussex: Lawrence Erlbaum Associates, 1994.
Davis 1986
    1. Davis JM, Andriukatis S. The natural course of schizophrenia and effective maintenance drug therapy. Journal of Clinical Psychopharmacology 1986;6(suppl 1):2‐10. - PubMed
Dencker 1980
    1. Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatrica Scandinavica 1980;61(supp 279):64‐76. - PubMed
Divine 1992
    1. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9. - PubMed
DoH 1996
    1. Department of Health, NHS Executive. Burdens of disease: a discussion document. HMSO 1996.
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80. - PubMed
Egger 1997
    1. Egger M, Davey‐Smith G, Schneider M, Minder CSO. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;13:629‐34. - PMC - PubMed
Gulliford 1999
    1. Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83. - PubMed
Guy 1976
    1. Guy W. In: National Institute of Mental Health, editor(s). ECDEU Assessment manual for psychopharmacology. Rockville, MD: DHEW publication No (ADM), 1976:124‐585.
Haynes 1979
    1. Haynes RB, Taylor WD, Sackett DL (Editors). Compliance in health care. Baltimore: John Hopkins University Press, 1979.
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Hirsch 1973
    1. Hirsch SR, Gaind R, Rohde PD. Outpatient maintenance of chronic schizophrenic patients with long‐acting fluphenazine: double‐blind placebo controlled trial. British Medical Journal 1973;1:633‐7. - PMC - PubMed
Jablensky 1992
    1. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen ASO. Schizophrenia: manifestations, incidence and course indifferent cultures. A World Health Organization ten‐country study. Psychological Medicine (Monograph Supplement) 1992;20:1‐97. - PubMed
Kane 1998
    1. Kane JM, Aguglia E, Carlo Altamura A, Guiterrez JLA, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropschopharmacology 1998;8:55‐66. - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352:609‐13. - PubMed
Moher 2001
    1. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA 2001;285:1987‐91. - PubMed
Petersson 1971
    1. Petersson H. Chronic schizophrenia treated with depot perphenazine. Nordic Journal of Psychiatry 1971;25(4):303‐8. - PubMed
Schulz 1994
    1. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994;272:125‐8. - PubMed
Simon 1995
    1. Simon G, Wagner E, Vonkorff M. Cost‐effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. Journal of Clinical Epidemiology 1995;48:363‐73. - PubMed
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75. - PubMed

Publication types

MeSH terms